Aurobindo buys Europe operations from Apotex
Executive Summary
Aurobindo is set to expand its European footprint, “particularly in the generics market of Eastern Europe”, by signing a definitive agreement to acquire for €74 million (US$87 million) in cash Apotex’ businesses in five countries: Belgium, the Czech Republic, the Netherlands, Poland and Spain. Slated to close in the next three-to-six months, the acquisition is subject to clearance by Dutch and Polish competition authorities. Apotex intends to “focus its resources on the Americas, where strong demand for its portfolio continues”.
You may also be interested in...
Aurobindo Integrates Apotex And Prepares For Sandoz
Aurobindo believes it has “substantially addressed” all requirements for an FTC go-ahead for its acquisition of Sandoz’s US dermatology and generic oral solids businesses. The integration of the acquired Apotex business in Europe is also shaping up.
Apotex Mystery: Why Has Accord BioPharma Taken Its Place In US Biosimilar Pegfilgrastim Litigation?
Court grants request to substitute Accord BioPharma for Apotex in Amgen infringement suit. Apotex says it has no plans to exit the biosimilar business.
Apotex Mystery: Why Has Accord BioPharma Taken Its Place In Pegfilgrastim Biosimilar Litigation?
Court grants request to substitute Accord BioPharma for Apotex in Amgen infringement suit. Apotex says it has no plans to exit the biosimilar business.